u/NeurotechNewsletter

I want to highlight this Neurotechnology database and ecosystem called Reccy Neuro. It’s got over 400 companies listed - pulls in real time news and updates. Check it out

Wanted to highlight reccy neuro - 400+ neurotech companies tracked with real time news and data. Plus a job board and an investor list

I spend a lot of time in the neurotech jobs market. It’s part of what I do. And the volume of open roles across BCI companies right now is unlike anything I’ve seen before.

What surprises people when I tell them this is that it’s not just Neuralink driving it. There are dozens of companies building in this space, most of them flying well under the radar, and a lot of them are hiring across the board right now. Engineering, clinical, regulatory, commercial.

For a field that gets written about as if it’s still 10 years away, the hiring activity is wild considering how much cash they’re burning through

Curious whether anyone else is paying attention to this side of things, or whether the gap between what’s actually happening and what gets covered is as wide for others as it seems to me

Sharing this because I think it deserves more attention than it has received.

Inner Cosmos has a penny-sized device embedded in the outer layer of the skull bone — under the skin, not inside the brain — that delivers TMS-equivalent cortical stimulation from home, every day, without a clinic visit. A psychiatrist monitors the brain data remotely and updates stimulation parameters wirelessly. The loop currently runs through the clinician rather than autonomously.

All three patients in the FDA Early Feasibility Study exceeded their best prior TMS outcomes. Two achieved full remission. One has remained in remission for over eighteen months. No serious adverse events. FDA has cleared them to proceed to a pivotal trial in the US and Australia.

Three patients is not a pivotal trial and this is years from being widely available. But for people who have failed multiple medications and multiple rounds of TMS, the idea that stimulation could be tuned weekly based on what the brain is actually doing feels like a meaningfully different kind of care.

Not posting to promote anything. Just sharing research I think is worth knowing about. Happy to answer questions about the science if useful.

A study published in Science Advances showed that low-intensity focused ultrasound aimed at the amygdala, delivered non-invasively through the skull, reduced fear conditioning in healthy adults. Fear memories formed less readily and extinguished more easily. No other brain region was affected.

For PTSD the clinical problem is precisely the opposite: fear memories form too readily and resist extinction despite efforts to process them. A non-invasive device that could intervene in that mechanism directly, without surgery and without the side effect profile of medication, would matter to a lot of people.

A company called Sanmai is building toward this. Pre-clinical, long path ahead, and I am deliberately not overstating where this sits in terms of availability. The mechanism has published human validation and the Series A was led by Reid Hoffman. Worth knowing about now rather than when it reaches mainstream coverage.

Sharing in case it is useful to anyone following this kind of research. No obligation to engage.

Something I keep coming back to: roughly 30 to 40% of people with epilepsy have drug-resistant disease. They have tried multiple medications and still have uncontrolled seizures. NeuroPace’s closed-loop device achieves 82% seizure reduction in this group. And yet 98% of people who could benefit from a device like that never receive one. The barrier is not the technology. It is surgery.

A small UT Austin spinout is building a focused ultrasound headset that targets the same deep brain structure as NeuroPace’s implant, without opening anyone’s skull. Very early stage — first patient trial not until early 2027 at the earliest. But the question they are asking feels important. What would access to effective epilepsy neuromodulation look like if surgery was not the price of entry?

Curious whether people here have had conversations with neurologists about device options, and what the barriers actually look like from the patient side.

Closed-loop neuromodulation has a reasonably well established clinical track record in implantable systems. NeuroPace’s RNS detects seizure onset signatures and responds within milliseconds.

Medtronic’s adaptive DBS reads beta oscillations from the subthalamic nucleus and adjusts stimulation in real time. Saluda’s ECAP-controlled SCS adjusts to the spinal cord’s own evoked response more than 100 times per second.

Two things I came across recently that struck me as architecturally novel. First: Fasikl closes its wearable tremor loop through a cloud AI platform rather than on the device itself, meaning the therapeutic model compounds learning across the entire patient population over time rather than within a single patient. Second: Nia Therapeutics is building a 60-channel implant that decodes neural state signatures associated with impaired memory encoding and stimulates the lateral temporal cortex in response — 19% improvement in delayed recall in a sham-controlled TBI trial, with no benefit from non-contingent stimulation.

The memory one in particular raises interesting questions about what closed-loop can target. Seizure onset signatures and beta oscillations have fairly well characterised biomarkers. Memory encoding state feels like a harder decoding problem. Anyone working on neural biomarker identification for cognitive states?